Opportunities
Search

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-10

Buyer: CHAMBRE DEP D'AGRICULTURE DE LA SOMME | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2027-11-10

Buyer: CHAMBRE DEP D'AGRICULTURE DE LA SOMME | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2027-11-10

Buyer: Hansel Oy | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-11-11

Buyer: Hansel Oy | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-11-11

Buyer: Presidenza del Consiglio dei ministri - Dipartimento per i servizi strumentali | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-11-12

The objective of the NIA Academic Leadership Career Award (K07) is to provide support for established investigators who have the expertise and leadership skills to enhance aging and/or Alzheimer's Disease (AD) and Alzheimers Disease Related Dementias (ADRD)research capacity within their academic institution. Through this award, investigators will endeavor to develop research and educational infrastructure, mentorship, and career development activities in support of new or emerging areas of aging and/or AD/ADRDresearch. These may include, but are not limited to, courses, curricula, research support, pilot funding, travel awards, visiting scholars, or networks. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. This NOFO is intended to support research education activities that enhance the knowledge of substance use and substance use disorder research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training.

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

FEDERAL GOVERNMENT OF NIGERIA CROSS RIVER STATE Nigeria Improved Child Survival Program for Human Capital MPA (P167156) Publication Issued Date: 30/10/2024   REQUEST FOR BIDS (RFB) Upgrading of 82 Selected Public Health Centers (PHCs) in Cross River State of Nigeria   INTRODUCTION: The Federal Government of Nigeria, on behalf of the Cross River State Government has received a Credit from the World Bank towards the cost of improving the utilization and quality of immunization plus and malaria services in selected states of the federation and intends to apply part of the proceeds towards the payments for the Upgrading of 82 Selected Public Health Centers (PHCs) in Cross River State. The Cross River State Government, through the Project Implementation Unit now invites sealed bids from eligible bidders for the Upgrading of 82 Selected Public Health Centers (PHCs) in Cross River State as detailed below: Lots No. Contact Description Contact Number Bid Security 1 Upgrading of 22 PHCs in BAKASSI, AKPABUYO, CALABAR MUNICIPALITY and CALABAR SOUTH LGAs of Cross River State   CRS/IMPACT/W/02/2024/A N21,544,858.487 2 Upgrading of 20 PHCs in OBUDU, OBANLIKU, BEKWARRA, YAKURR and ABI LGAs of Cros...

Buyer: МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ - СВЕТИ НИКОЛАЙ ЧУДОТВОРЕЦ ЕООД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-11-14

Buyer: LESY Slovenskej republiky, štátny podnik | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-11-15

The purpose of this Notice of Funding Opportunity (NOFO) is to leverage NICHD clinical research Network infrastructure relevant to infants, children, women, pregnant and lactating women, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase (UG3) and a full enrollment and clinical trial implementation phase (UH3). Applications submitted in response to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases. A UG3 project (phase I) that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award (phase II). This NOFO provides an opportunity to leverage NICHD clinical research Network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. Applications must be submitted as investigator-initiated, multi-Project Director/Principal Investigator (PD/PI) grant applications in conjunction with the respective NICHD-supported Network Data Coordinating Center (DCC), or equivalent as determined by the NICHD.

Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to elucidate a role for understudied proteins in rare disease. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This NOFO is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins within the context of rare disease.

This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

This Notice of Funding Opportunity (NOFO) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for long-term viral suppression or eradication. Finally, health-impeding social determinants of health may affect CCCs or viral reservoirs within NIDDK's mission through multiple pathways.